a 46-year-old woman
Biopsy-confirmed IgA nephropathy with microscopic hematuria and nephritic-range proteinuria
She had already tried six months of high-dose prednisone with a RAAS blocker and an SGLT2 inhibitor, but it did not work and gave her strong steroid side effects. Doctors switched her to targeted-release budesonide, a steroid that acts mostly in the gut. Over six months her urine protein dropped from 2,536 mg a day to 66 mg a day, the blood in her urine went away, and her eGFR rose from 65 to 80. The steroid side effects did not come back.
In one woman with IgA nephropathy who failed and could not tolerate full-body steroids, switching to targeted-release budesonide sharply lowered her urine protein and improved her kidney filtering over six months.
- Six months of high-dose prednisone plus a RAAS blocker and an SGLT2 inhibitor did not help her and caused marked steroid toxicity (cushingoid side effects).
- After switching to targeted-release budesonide, her urine protein fell from 2,536 mg/day to 66 mg/day over six months.
- Her blood in the urine completely went away, and her estimated kidney filtering (eGFR) rose from 65 to 80 mL/min/1.73 m2.
- The budesonide was well tolerated, and the earlier steroid side effects did not come back.
- This worked for a specific kind of patient: someone with IgA nephropathy who had already failed or could not handle standard whole-body steroids.
Why it might work
The paper frames the problem this way: standard steroids like prednisone act throughout the whole body, which can cause strong side effects and still may not control the disease. Targeted-release budesonide is designed to act in a more focused way rather than everywhere at once. In this one case, that focused approach lowered the immune-driven kidney inflammation enough to drop her protein loss and improve her filtering, while sparing her the body-wide steroid side effects she had before. The abstract does not spell out the biology beyond calling the drug targeted-release, so the exact reason it worked here is not fully described.
The honest limits
- This is a single patient (n=1). One person getting better does not prove the treatment works for most people with stage 3 CKD or IgA nephropathy.
- eGFR is an estimate, not a direct measurement, so the rise from 65 to 80 may partly reflect normal variation rather than true kidney repair.
- Follow-up was only six months, so whether the improvement lasts is unknown.
- The abstract discloses no conflicts of interest and reports no repeat kidney biopsy or other long-term safety data, so those cannot be confirmed from the source.
- Do I have the kind of IgA nephropathy, and the level of protein in my urine, where targeted-release budesonide would even be considered?
- I have stage 3 CKD; how would you weigh the possible benefit of budesonide against its risks for someone at my kidney function?
- If we tried it, how and how often would you check whether it is actually helping, and what would tell us to stop?